Myelofibrosis, extensive splenomegaly, and symptomatic burden are significantly improved for patients with MPN by JAK1 and JAK2 inhibition; however, some major needs in this patient group are still largely unmet.
This fact sheet examines the various kinds of chronic myeloproliferative neoplasms, and the tests utilized to detect and diagnose them.
A case of simultaneous PAP and MPN diagnoses demonstrate the importance of evaluating for GM-CSF autoantibodies to distinguish autoimmune and secondary forms of PAP.
Genetic Underpinnings of Splanchnic Vein Thrombosis in Myeloproliferative Neoplasms May Provide New InsightsApril 19, 2017
Risk factors for splanchnic vein thrombosis in patients with myeloproliferative neoplasms are multifactorial, involving both environmental and host genetic factors.
Simtuzumab is well-tolerated but has inconsistent clinical benefit for patients with myelofibrosis.
In this study, researchers measured the psychological manifestations among patients with BCR-ABL-negative MPNs to determine the effects of anxiety, distress, and depression on symptom burden in this patient population.
Ruxolitinib is proven superior to best available therapy for polycythemia vera with inadequate response or intolerance of hydroxyurea. This study evaluates the impact of continued hydroxyurea vs switching to ruxolitinib on disease-related symptom burden.
Evidence suggests that women with myeloproliferative neoplasms have a higher risk of maternal and fetal complications. In this data analysis, researchers evaluated outcomes for pregnant women with essential thrombocythemia, polycythemia, or myelofibrosis and their infants.
This fact examines the possible causes, risk factors, symptoms, and treatments associated with polycythemia vera.
The clinical course of a patient with polycythemia vera and proteinuria whose biopsy lead to a diagnosis of focal segmental glomerulosclerosis is described.
Patients with myeloproliferative neoplasms, such as polycythemia vera and myelofibrosis, and their physicians frequently view the assessment of disease prognosis, disease burden, and treatment goals differently.
Ruxolitinib is an effective long-term treatment option for patients with polycythemia resistant or intolerant to hydroxyurea, according to a study presented at the 2016 European Hematology Association Congress.
- Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab
- Health Care Expansion Tied to Increased Rates of Surgical Treatment of Thyroid Cancer
- Including a PI3-Kinase Inhibitor with an PARP Inhibitor Improves Tumor Shrinkage in Patients with Resistant Ovarian Cancer
- JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed
- Hormone Refractory Prostate Cancer Responds to Abiraterone Acetate in Some Cases
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- Primary Care Physicians Surveyed on Breast Cancer Screening Practices
- Low Acculturated Latina Women Reported Breast Cancer Treatment Experience Differently Than Other Groups
- Cost and Complication Rates Differ Among Early Breast Cancer Treatment Options
- Distress Management Tool Gets an Update, Patient Version
- PSA Screening Rates Level Off in United States
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|